Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00126334-200201010-00015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen.
Clin Infect Dis
December 2024
Université Paris Cité, Inserm, IAME, F-75018, Paris, France.
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.
View Article and Find Full Text PDFQuantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays.
J Clin Virol
December 2024
Clinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPaz, Madrid, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Introduction: There are few validated commercially available HIV-2 assays for the measurement of viral load. Our aim was to compare three commercial assays for the quantification of HIV-2 viral load in plasma of patients with HIV-2 infection from our hospital.
Material And Methods: We conducted a retrospective study at our tertiary-care hospital, analyzing samples from patients with known HIV-2 infection collected between 2022 and 2023.
Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors.
ACS Bio Med Chem Au
October 2024
Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Darunavir, a frontline treatment for HIV infection, faces limitations due to emerging multidrug resistant (MDR) HIV strains, necessitating the development of analogs with improved activity. In this study, a combinatorial in silico approach was used to initially design a series of HIV-1 PI analogs with modifications at key sites, P1' and P2', to enhance interactions with HIV-1 PR. Fifteen analogs with promising binding scores were selected for synthesis and evaluated for the HIV-1 PR inhibition activity.
View Article and Find Full Text PDFLenacapavir: Playing the Long Game in the New Era of Antiretrovirals.
Clin Pharmacol Ther
September 2024
Center for Clinical Pharmaceutical Sciences, Department of Pharmacy & Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
The mainstay of antiretroviral therapy (ART) has been combination oral therapy. While oral ART is highly effective, nonadherence remains a chief concern. Addressing this concern in recent years is the emergence of long-acting antiretrovirals for the treatment and prevention of HIV-1 infection.
View Article and Find Full Text PDFA Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia.
Yonsei Med J
October 2024
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Article Synopsis
- Lenacapavir is a new type of medicine for people with a tough form of HIV that doesn't respond to many other treatments.
- A 43-year-old man who has struggled with HIV since 2005 finally got help when he tried lenacapavir along with other medicines, and it worked!
- After taking lenacapavir, his viral levels dropped and his immune system started to get better for 8 months, showing it can be a good option for patients with very few choices.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!